Not strictly stem cells, but consequence for them at a regulatory level, with the EMA approving an off-the-shelf “allogeneic” cellular therapy - it and the FDA having only approving only autologous CAR T-Cell therapies to date:
https://www.labiotech.eu/in-depth/atara-biotherapeutics-ebvallo/Before the peanut brigade deride me for relevance to CYP, its a step in the right direction and there a literally dozens of companies working on induced pluripotent stem cells (iPSCs) sources for an unlimited supply of universal allogeneic CAR T cells for cancer immunotherapy, given the obvious limitation of autologous cells and shall we say, potency/consistency issues with single donor derived supplies.
I am a holder of MSB [donor], OCC [autologous] and CYP [ISPC] stem cell companies in Australia, and various others in the US. Unlike the hand-baggers on these threads, I believe all can co-exist with, to some degree even, mutually beneficial success.
(20min delay)